PCK1 suppresses #HepatocellularCarcinoma stemness & #tumorigenesis by activating the #HippoPathway via YAP inhibition, enhances #sorafenib sensitivity, and supports combined therapy with verteporfin as a promising strategy against #LiverCancer.

#OpenAccess: doi.org/10.1016/j.ge...

Silencing MFN2 Drives WNT/β-catenin Nucleation to Reduce Sorafenib Sensitivity in Hepatocellular Carcinoma Cells

Low MFN2 in #HepatocellularCarcinoma activates β-catenin/EMT signaling, boosting invasion and #sorafenib resistance; MFN2 overexpression restores drug sensitivity, highlighting MFN2 as a potential therapeutic target to overcome #drugresistance.
Read: doi.org/10.1007/s115...

#CancerAssociatedFibroblasts -derived fibronectin EDA drives #Sorafenib resistance in #HCC via SHMT1 activation, highlighting a novel fibroblast-tumor interaction that governs therapeutic response in #LiverCancer.

#OpenAccess: doi.org/10.1016/j.ge...

El sorafenib ofrece una tasa de beneficio clínico del 58,3 % en perros con carcinoma irresecable El sorafenib fue bien tolerado y proporcionó un beneficio clínico medible en perros con carcinomas avanzados irresecables  ...

El #sorafenib fue bien tolerado y proporcionó un beneficio clínico medible en #perros con #carcinomas avanzados irresecables

#Article in #MedComm
circRNA-SORE/UBQLN1/GPX4 Mediates the Acquisition of Sorafenib Resistance in Hepatocellular Carcinoma Through Inhibition of Ferroptosis doi.org/10.1002/mco2...

#circRNA #ferroptosis #sorafenib #resistance #UBQLN1 #GPX4

Kexing Biopharm Expands Global Presence with Sorafenib Generic Approvals in Egypt and Peru Kexing Biopharm has received approvals for its Sorafenib Tosylate Tablets generic in Egypt and Peru, boosting access to cancer treatment in these regions.

Kexing Biopharm Expands Global Presence with Sorafenib Generic Approvals in Egypt and Peru #China #Shenzhen #Kexing_Biopharm #Sorafenib #Tosylate_Tablets

LEVIATHAN Study Results: Lenvatinib vs Sorafenib as 2L Treatment for Hepatocellular Carcinoma - OncoDaily Lenvatinib shows superior survival over sorafenib as second-line therapy after A+B in HCC, per multinational real-world LEVIATHAN study.

LEVIATHAN Study Results: Lenvatinib vs Sorafenib as 2L Treatment for Hepatocellular Carcinoma

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LEVIATHAN #Lenvatinib #Sorafenib #HepatocellularCarcinoma #HCC

APOLLO Trial: OS Benefit with Anlotini Penpulimab in HCC APOLLO trial shows that penpulimab plus anlotinib significantly improves survival outcomes over sorafenib in unresectable HCC.

New Paper Alert: APOLLO Trial. Anlotinib Plus Penpulimab vs Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma

oncodaily.com/opinion/apol...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #APOLLO #Anlotinib #Penpulimab #Sorafenib #HCC

Sorafenib (Nexavar): Uses in Cancer, Side Effects, Dosage, Expectations, and More - OncoDaily learn about sorafenib (Nexavar), its uses in cancer treatment, side effects, dosage, adminstration and what to expect during treatment.

Sorafenib (Nexavar): Uses in Cancer, Side Effects, Dosage, Expectations, and More

oncodaily.com/drugs/sorafe...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Sorafenib #Nexavar #HCC #RCC #ThyroidCancer #TargetTherapy

Novel ICI–TKI combination outplays sorafenib in advanced HCC First-line treatment with anlotinib plus penpulimab significantly improves the outcomes of patients with unresectable hepatocellular carcinoma relative to sorafenib.

#MedNews - First-line treatment with #anlotinib plus #penpulimab significantly improves the outcomes of patients with unresectable hepatocellular carcinoma relative to #sorafenib.

Full story 👉 buff.ly/aA3W8IV

#OncSky #HCC

PCK1 attenuates tumor stemness via activating the Hippo signaling pathway in hepatocellular carcinoma

PCK1 attenuates #CancerStemness, inhibits #tumorigenicity, & increases the sensitivity of hepatoma cells to #sorafenib by promoting YAP phosphorylation, while loss of PCK1 enhances the stemness of hepatoma cells by promoting nuclear translocation of YAP. #medsky

#OpenAccess: www.sciencedirect.co...

Cancer-associated fibroblasts derived fibronectin extra domain A promotes sorafenib resistance in hepatocellular carcinoma cells by activating SHMT1

This study identifies fibronectin extra domain A (FN-EDA) as a promising target for both predicting and overcoming resistance to #sorafenib treatment in patients with advanced #hepatocellularcarcinoma (HCC). #medsky

#OpenAccess: www.sciencedirect.com/science/arti...

STIM1 promotes acquired resistance to sorafenib by attenuating ferroptosis in hepatocellular carcinoma

STIM1 increases the transcription of SLC7A11 through the SOCE-CaN-NFAT pathway, resulting in increased glutathione synthesis, which leads to #Ferroptosis insensitivity and #sorafenib resistance in #HepatocellularCarcinoma. #medsky

#OpenAccess: buff.ly/pQid0bm

Cancer-associated fibroblasts derived fibronectin extra domain A promotes sorafenib resistance in hepatocellular carcinoma cells by activating SHMT1

This new study identifies Fibronectin extra domain A (FN-EDA) as a promising target for both predicting and overcoming resistance to #sorafenib treatment in patients with advanced #hepatocellularcarcinoma (HCC).

#OpenAccess: www.sciencedirect.co...

Cancer-associated fibroblasts derived fibronectin extra domain A promotes sorafenib resistance in hepatocellular carcinoma cells by activating SHMT1

This new study identifies Fibronectin extra domain A (FN-EDA) as a promising target for both predicting and overcoming resistance to #sorafenib treatment in patients with advanced #hepatocellularcarcinoma (HCC).

#OpenAccess: https://buff.ly/4hvnOaj

New Paper Alert: Hepatocellular Carcinoma - Stereotactic Body Radiotherapy vs Sorafenib Alone in the NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial - JAMA Oncology - OncoDaily New paper alert on Phase 3 RCT comparing SBRT plus Sorafenib to Sorafenib alone in treating locally advanced hepatocellular carcinoma.

New Paper Alert: Hepatocellular Carcinoma – Stereotactic Body Radiotherapy vs Sorafenib Alone in the NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial – JAMA Oncology

oncodaily.com/library/new-...

#AdvancedHCC #AdvancedHepatocellularCarcinoma #HCC #NewPaperAlert #SBRT #Sorafenib #Medicine

🚨 New paper alert! 📄

From 2007-2017, #sorafenib was the only systemic option for #HCC. Post-2017, 9 new therapies emerged!

We studied:
📊 Treatment trends
📈 Survival shifts

📌 First registry study on how these therapies impact the U.S.A

Read more!
acsjournals.onlinelibrary.wiley.com/doi/abs/10.100

US Pharmacopeia News | Labmix24 Stay up-to-date on new USP product releases, training courses and other announcements.

New US Pharmacopeia reference standards and Quality Solution Sheets are available at @Labmix24. Learn more: labmix24.com/en/pharmaceu...
 #Nadolol #Paliperidone #Pantoprazole #Pemetrexed #Permethrin #Pentazocine #Pimecrolimus #Piperacillin #Propranolol #Regorafenib #Rotigotine #Sirolimus #Sorafenib

more questions than answers but a few obvious conclusions: #HCC therapy in the LEAP-002 and COSMIC-312 ( #cabozantinib #atezolizumab vs. #sorafenib ) era is different from SHARP, REFLECT and many older 1L therapies. Subsequent therapy after progression on study was NOT RANDOM.

@ILCAnews Dr. Meyer @ucl cites some examples of “markers” of #HCC response to systemic rx or lacktherof
⬆️AFP and #ramucirumab in 2L
#HCV pos and #sorafenib (maybe)
#NAFLD and potential resistance to ICIs @CancerInflam
Non viral hepatitis and #durvalumab #tremelimumab #ilca22

@ILCAnews Drs. Tim Meyer @ucl and Katie Kelley @UCSFMedicine review the current state of #HCC systemic therapy #sorafenib #lenvatinib #cabozantinib #pembrolizumab #atezolizumab #bevacizumab #durvalumab #tremelimumab #camrelizumab #tislelizumab #rivoceranib #ilca22

#Tislelizumab meets FL non inferiority OS endpoint vs. #sorafenib in ph3 study of unresectable #HCC. More @myESMO #livertwitter...

HIMALAYA #HCC abstract out. Positive study but many questions. Do we need treme at all? Long DOR. 30% alive at 3 y. #sorafenib aging like fine wine. #GI22 $AZN http://newsfilter.io/a/98cf429f324b…

@AASLDtweets dr. Al khoueiri @USC #sorafenib experienced #HCC patient overall survival with #opdivo was 15 months vs. 29 months for sorafenib naive patients! We’ve come a long way from a decade ago #livermtg18

@EASLedu my conclusions after #SORAMIC, SARAH and SIRVENIB: there is no benefit of adding #SIRT to #sorafenib in advanced #HCC #ILC2018

@EASLedu @EASLnews Dr RIcke: #SORAMIC #HCC RCT study of #SIRT+ #sorafenib vs. sorafenib fraught with protocol violations But basically shows no difference in OS #ILC2018

@EASLedu Dr reig: what is the best 2nd line #HCC option? It depends! #sorafenib tolerance, hepatitis infected or not, treatment history...all factor into this. #ilc2018

@EASLedu @EASLnews Dr RIcke reviews locoregional therapies and alludes that SARAH and SIRVENIB RCTs which showed no OS benefit of SIRT vs. #sorafenib are flawed. This assertion flies in the face of overwhelming evidence imo #ILC2018

@EASLedu CheckMate-040 study of #nivolumab in #HCC #sorafenib failures. Note overall survival not yet reached for #HCV and #HBV #ilc2017

@EASLedu Highlight 2 from #ilc2017 are #nivolumab data in #HCC #sorafenib failures showing high disease control rate and survival